WO2000031285A1 - Vecteurs de fourniture de genes comportant un tropisme tissulaire et destines a des cellules de muscles lisses et/ou des cellules endotheliales - Google Patents
Vecteurs de fourniture de genes comportant un tropisme tissulaire et destines a des cellules de muscles lisses et/ou des cellules endotheliales Download PDFInfo
- Publication number
- WO2000031285A1 WO2000031285A1 PCT/NL1999/000717 NL9900717W WO0031285A1 WO 2000031285 A1 WO2000031285 A1 WO 2000031285A1 NL 9900717 W NL9900717 W NL 9900717W WO 0031285 A1 WO0031285 A1 WO 0031285A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adenovirus
- cells
- fiber
- protein
- vehicle according
- Prior art date
Links
- 230000005100 tissue tropism Effects 0.000 title claims abstract description 48
- 210000000329 smooth muscle myocyte Anatomy 0.000 title claims abstract description 43
- 210000002889 endothelial cell Anatomy 0.000 title claims abstract description 39
- 239000013598 vector Substances 0.000 title claims description 99
- 238000001476 gene delivery Methods 0.000 title claims description 29
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 286
- 241000700605 Viruses Species 0.000 claims abstract description 124
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 57
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 55
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 55
- 210000000234 capsid Anatomy 0.000 claims abstract description 51
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 218
- 108090000623 proteins and genes Proteins 0.000 claims description 150
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 241001135569 Human adenovirus 5 Species 0.000 claims description 73
- 101710145505 Fiber protein Proteins 0.000 claims description 69
- 239000012634 fragment Substances 0.000 claims description 58
- 210000005229 liver cell Anatomy 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 15
- 101150076401 16 gene Proteins 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 210000000987 immune system Anatomy 0.000 claims description 3
- 102000012936 Angiostatins Human genes 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- 102000007592 Apolipoproteins Human genes 0.000 claims description 2
- 108010071619 Apolipoproteins Proteins 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 102100039064 Interleukin-3 Human genes 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229940076264 interleukin-3 Drugs 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims 1
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 239000000835 fiber Substances 0.000 description 102
- 235000018102 proteins Nutrition 0.000 description 63
- 208000015181 infectious disease Diseases 0.000 description 49
- 230000014509 gene expression Effects 0.000 description 30
- 239000003981 vehicle Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 230000027455 binding Effects 0.000 description 21
- 238000004806 packaging method and process Methods 0.000 description 20
- 239000002245 particle Substances 0.000 description 20
- 108060001084 Luciferase Proteins 0.000 description 19
- 239000005089 Luciferase Substances 0.000 description 19
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 108700019146 Transgenes Proteins 0.000 description 17
- 238000001415 gene therapy Methods 0.000 description 17
- 108090000565 Capsid Proteins Proteins 0.000 description 16
- 102100023321 Ceruloplasmin Human genes 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 13
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 13
- 239000005090 green fluorescent protein Substances 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000001413 cellular effect Effects 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 102000006495 integrins Human genes 0.000 description 11
- 108010044426 integrins Proteins 0.000 description 11
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000037430 deletion Effects 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000010361 transduction Methods 0.000 description 9
- 230000026683 transduction Effects 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 210000003752 saphenous vein Anatomy 0.000 description 5
- 210000003606 umbilical vein Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001428587 Human adenovirus 16 Species 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 108010084938 adenovirus receptor Proteins 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 102000043827 human Smooth muscle Human genes 0.000 description 2
- 108700038605 human Smooth muscle Proteins 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 description 1
- 101710176411 Coxsackievirus and adenovirus receptor Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 101710164463 Preterminal protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004912 pericardial fluid Anatomy 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Definitions
- the present invention provides adenovirus derived vectors which can be used as cassettes to insert different adenoviral genes from different adenoviral serotypes at the required sites.
- a vector capable of producing a chimaeric adenovirus whereby of course also a gene of interest can be inserted (for instance at the site of El of the original adenovirus) .
- the chimaeric adenovirus to be produced can be adapted to the requirements and needs of certain hosts in need of gene therapy for certain disorders.
- a packaging cell will generally be needed in order to produce sufficient amount of safe chimaeric adenoviruses .
- Chimaeric viruses having only one non-native sequence in addition to an insertion or replacement of a gene of interest in the El region are also within the scope of the invention.
- An immunogenic response to adenovirus that typically occurs is the production of neutralizing antibodies by the host. This is typically a reason for selecting a capsid protein like penton, hexon and/or fiber of a less immunogenic serotype .
- Restenosis is characterized by progressive arterial remodeling, extracellular matrix formation and intimal hyperplasia at the site of angioplasty (Schwartz et al , 1993; Carter et al , 1994; Shi et al,1996).
- NO is one of the vasoactive factors shown to be lost after PTCA-induced injury to the endothelial barrier (Lloyd Jones and Bloch, 1996) .
- restoration of NO levels after balloon-induced injury by means of adenoviral delivery of ceNOS may prevent restenosis (Varenne et al, 1998) .
- construct pWE/Ad.AflIIrITRfibl6 comprising Ad5 sequence 3534-31094 and 32794-35938, further comprising an adenovirus 16 gene encoding fiber protein.
- HUVsmc were infected with increasing amounts of virus particles per cell (156, 312, 625, 1250, 2500, 5000) .
- the fiber mutant all carry the Luciferase marker gene (Ad5Fibll .Luc : 1.1 x 10 12 vp/ml; Ad5Fib35Luc: 1.4 x 10 12 vp/ml ; Ad5Fib51Luc: 1.0 x 10 12 vp/ml) .
- efficient infection of SMC is not a general trade of all subgroup B fiber molecules.
- Clearly fiber 16 an fiber 11 are better suited for infection of SMC than fiber 35 and fiber 51. Nevertheless, all subgroup B fiber mutants ' tested infect SMC better as compared to Ad5.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne un vecteur de fourniture d'acide nucléique comportant ou ayant comporté au moins un tropisme tissulaire et destiné à des cellules de muscles lisses et/ou des cellules endothéliales. Dans un aspect de la présente invention, ce vecteur de fourniture de gènes est une capside virale ou une partie fonctionnelle, un dérivé et/ou un analogue de cette capside virale. De préférence, la capside virale est une capside adénovirale. De préférence, l'adénovirus est un adénovirus du sous-groupe B, de préférence un adénovirus 16. De préférence, le tropisme tissulaire est compris dans au moins une partie de détermination de tropisme tissulaire d'une protéine fibreuse adénovirale ou un dérivé fonctionnel et/ou un analogue de cette protéine. L'invention concerne également des méthodes de traitement de maladies, de préférence de maladies cardiovasculaires.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2318492A CA2318492C (fr) | 1998-11-20 | 1999-11-22 | Vecteurs de fourniture de genes comportant un tropisme tissulaire et destines a des cellules de muscles lisses et/ou des cellules endotheliales |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98203921.6 | 1998-11-20 | ||
| EP98203921 | 1998-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000031285A1 true WO2000031285A1 (fr) | 2000-06-02 |
Family
ID=8234363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NL1999/000717 WO2000031285A1 (fr) | 1998-11-20 | 1999-11-22 | Vecteurs de fourniture de genes comportant un tropisme tissulaire et destines a des cellules de muscles lisses et/ou des cellules endotheliales |
Country Status (12)
| Country | Link |
|---|---|
| JP (1) | JP4683682B2 (fr) |
| AT (1) | ATE296894T1 (fr) |
| AU (1) | AU770780B2 (fr) |
| CA (1) | CA2318492C (fr) |
| DE (1) | DE69925567T2 (fr) |
| ES (1) | ES2244145T3 (fr) |
| IL (1) | IL133032A (fr) |
| MX (1) | MXPA99010682A (fr) |
| NO (1) | NO995697L (fr) |
| NZ (1) | NZ501214A (fr) |
| WO (1) | WO2000031285A1 (fr) |
| ZA (1) | ZA997213B (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002024730A2 (fr) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Vecteurs de transfert de genes munis d'un tropisme tissulaire pour des cellules dendritiques |
| WO2004106532A1 (fr) * | 2003-05-27 | 2004-12-09 | Cytos Biotechnology Ag | Polypeptides modifies destines a cibler l'entree dans les cellules des adenovirus de sous-type b |
| US6849446B2 (en) | 2000-05-31 | 2005-02-01 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
| US11253608B2 (en) | 2017-05-26 | 2022-02-22 | Epicentrx, Inc. | Recombinant adenoviruses carrying transgenes |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU776067B2 (en) * | 1999-03-04 | 2004-08-26 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
| US6905678B2 (en) * | 2001-07-07 | 2005-06-14 | Crucell Holland B.V. | Gene delivery vectors with cell type specificity for mesenchymal stem cells |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997020051A2 (fr) * | 1995-11-28 | 1997-06-05 | Genvec, Inc. | Vecteurs et procedes permettant de transferer des genes dans des cellules |
| WO1998022609A1 (fr) * | 1996-11-20 | 1998-05-28 | Genzyme Corporation | Vecteurs d'adenovirus chimeriques |
| WO1998033929A2 (fr) * | 1997-01-30 | 1998-08-06 | Centre National De La Recherche Scientifique (Cnrs) | Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus |
| WO1998044121A1 (fr) * | 1997-04-02 | 1998-10-08 | Transgene S.A. | Fibre adenovirale modifiee et adenovirus cibles |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| ES2333425T5 (es) * | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
-
1999
- 1999-11-18 IL IL133032A patent/IL133032A/en not_active IP Right Cessation
- 1999-11-19 ES ES99203878T patent/ES2244145T3/es not_active Expired - Lifetime
- 1999-11-19 MX MXPA99010682A patent/MXPA99010682A/es not_active IP Right Cessation
- 1999-11-19 ZA ZA9907213A patent/ZA997213B/xx unknown
- 1999-11-19 AT AT99203878T patent/ATE296894T1/de not_active IP Right Cessation
- 1999-11-19 DE DE69925567T patent/DE69925567T2/de not_active Expired - Lifetime
- 1999-11-19 NO NO995697A patent/NO995697L/no not_active Application Discontinuation
- 1999-11-22 AU AU59600/99A patent/AU770780B2/en not_active Ceased
- 1999-11-22 CA CA2318492A patent/CA2318492C/fr not_active Expired - Fee Related
- 1999-11-22 WO PCT/NL1999/000717 patent/WO2000031285A1/fr unknown
- 1999-11-22 NZ NZ501214A patent/NZ501214A/en not_active IP Right Cessation
- 1999-11-22 JP JP33203399A patent/JP4683682B2/ja not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997020051A2 (fr) * | 1995-11-28 | 1997-06-05 | Genvec, Inc. | Vecteurs et procedes permettant de transferer des genes dans des cellules |
| WO1998022609A1 (fr) * | 1996-11-20 | 1998-05-28 | Genzyme Corporation | Vecteurs d'adenovirus chimeriques |
| WO1998033929A2 (fr) * | 1997-01-30 | 1998-08-06 | Centre National De La Recherche Scientifique (Cnrs) | Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus |
| WO1998044121A1 (fr) * | 1997-04-02 | 1998-10-08 | Transgene S.A. | Fibre adenovirale modifiee et adenovirus cibles |
Non-Patent Citations (4)
| Title |
|---|
| FALLAUX F ET AL: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", HUM GENE THER., vol. 9, 1 September 1998 (1998-09-01), pages 1909 - 1917, XP002111070 * |
| GALL J ET AL: "Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes", J VIROL., vol. 70, no. 4, April 1996 (1996-04-01), pages 2116 - 2123, XP002050655 * |
| ROELVINK P ET AL: "The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F", J VIROL., vol. 72, no. 10, October 1998 (1998-10-01), XP002111071 * |
| WICKHAM T ET AL: "Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies", J VIROL., vol. 70, no. 10, October 1996 (1996-10-01), pages 6831 - 6838, XP002911349 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US7968087B2 (en) | 1998-11-20 | 2011-06-28 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US6849446B2 (en) | 2000-05-31 | 2005-02-01 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
| WO2002024730A2 (fr) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Vecteurs de transfert de genes munis d'un tropisme tissulaire pour des cellules dendritiques |
| WO2002024730A3 (fr) * | 2000-09-20 | 2002-06-27 | Crucell Holland Bv | Vecteurs de transfert de genes munis d'un tropisme tissulaire pour des cellules dendritiques |
| US9228205B2 (en) | 2000-11-15 | 2016-01-05 | Crucell Holland B.V. | Complementing cell lines |
| WO2004106532A1 (fr) * | 2003-05-27 | 2004-12-09 | Cytos Biotechnology Ag | Polypeptides modifies destines a cibler l'entree dans les cellules des adenovirus de sous-type b |
| US11253608B2 (en) | 2017-05-26 | 2022-02-22 | Epicentrx, Inc. | Recombinant adenoviruses carrying transgenes |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4683682B2 (ja) | 2011-05-18 |
| CA2318492A1 (fr) | 2000-06-02 |
| DE69925567T2 (de) | 2006-05-04 |
| ATE296894T1 (de) | 2005-06-15 |
| IL133032A (en) | 2007-06-03 |
| NO995697L (no) | 2000-05-22 |
| ES2244145T3 (es) | 2005-12-01 |
| AU770780B2 (en) | 2004-03-04 |
| ZA997213B (en) | 2000-05-22 |
| DE69925567D1 (de) | 2005-07-07 |
| CA2318492C (fr) | 2010-05-11 |
| NZ501214A (en) | 2002-02-01 |
| AU5960099A (en) | 2000-05-25 |
| NO995697D0 (no) | 1999-11-19 |
| JP2000157289A (ja) | 2000-06-13 |
| IL133032A0 (en) | 2001-03-19 |
| MXPA99010682A (es) | 2002-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7968087B2 (en) | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells | |
| US6803234B2 (en) | Gene delivery vectors with cell type specificity for primary human chondrocytes | |
| CA2364499C (fr) | Transduction de cellules ressemblant a des fibroblastes ou a des macrophages et moyens a cet effet | |
| AU2002315947B2 (en) | Adenoviral vectors with cell type specificity for mesenchymal cells | |
| AU2002315947A1 (en) | Adenoviral vectors with cell type specificity for mesenchymal cells | |
| US20060104953A1 (en) | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof | |
| EP1020529B1 (fr) | Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales | |
| US6869936B1 (en) | Means and methods for fibroblast-like or macrophage-like cell transduction | |
| AU770780B2 (en) | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells | |
| EP1191105A1 (fr) | Vecteurs d'apport de gènes munis d'un tropisme pour les T-lymphocytes | |
| EP1191104A1 (fr) | Vehicules de trasport génique et leur utilisation dans preparations medicaux et de vaccines | |
| EP1195440A1 (fr) | Vecteurs d'apport de genes pour les cellules souches | |
| AU2001294348B2 (en) | Transduction of chondrocytes using adenoviral vectors | |
| CA2407518A1 (fr) | Vecteurs d'adenovirus a fibres sans spicule, et leurs utilisations | |
| NZ527634A (en) | Means and methods for synoviocyte cell transduction | |
| AU2001294348A1 (en) | Transduction of chondrocytes using adenoviral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AZ BA BB BG BR BY CA CN CR CU CZ DM GD GE GH GM HR HU ID IN IS KE KG KP KR KZ LC LK LR LS MA MD MG MN MW PL RU SD SG SK SL TJ TM TR TT TZ UA UG UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| ENP | Entry into the national phase |
Ref document number: 2318492 Country of ref document: CA |